BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32562509)

  • 1. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
    Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
    J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
    Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
    J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
    Sakamoto S; Sato K; Takita Y; Izumiya Y; Kumagai N; Sudo K; Hasegawa Y; Yokota H; Akamine Y; Okuda Y; Asano M; Takeda M; Sano M; Miura M; Nakayama K
    Invest New Drugs; 2020 Dec; 38(6):1687-1695. PubMed ID: 32436059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
    Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y
    Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
    Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
    Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
    Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
    Xiang Q; Li C; Zhao X; Cui YM
    J Clin Pharm Ther; 2017 Jun; 42(3):345-349. PubMed ID: 28244604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
    Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
    Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
    Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
    Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
    Guo L; Wang S; Wan Z; Ni S; Xu B; Zhao X; Liu L
    J Clin Pharm Ther; 2020 Aug; 45(4):632-637. PubMed ID: 32379356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
    Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
    Kim KA; Joo HJ; Park JY
    Eur J Clin Pharmacol; 2011 Feb; 67(2):129-34. PubMed ID: 20972558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.
    Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM
    J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.